We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+113.09%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.17%
10 Year Est. Return
+19,957,666.26%
AUM
$452M
AUM Growth
+$130M
(+40%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-4.08%
Top 10 Holdings %
Top 10 Hldgs %
10.66%
Holding
352
New
147
Increased
15
Reduced
84
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AWH
Aspira Women's Health Inc. Common Stock
AWH
|
+$3.03M |
| 2 |
OneSpan
OSPN
|
+$2.96M |
| 3 |
Anterix
ATEX
|
+$2.79M |
| 4 |
Calix
CALX
|
+$2.73M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$3.54M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$3.44M |
| 3 |
Teladoc Health
TDOC
|
+$3.2M |
| 4 |
Krystal Biotech
KRYS
|
+$3M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.95% |
| 2 | Technology | 21.89% |
| 3 | Consumer Discretionary | 16.2% |
| 4 | Industrials | 10.05% |
| 5 | Consumer Staples | 6.72% |
Similar funds
NEPWA
RWM
MCM
HP
OMG
RB
BGC
ICCFIA
EAM Investors's Q2 2020 Portfolio in Review
As of Q2 2020, EAM Investors held 352 positions worth $452M, up 40% from $322M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
EAM Investors withdrew a net $18.5M in Q2 2020, closing 97 positions and reducing 84 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $3.44M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 40% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Investors opened a new position in Aspira Women's Health Inc. Common Stock worth $2.61M.
- EAM Investors's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 45,313 shares worth $2.61M.
- EAM Investors added most to Purple Innovation in Q2 2020, an estimated $2.04M increase.
- EAM Investors's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $3.54M.
- EAM Investors fully exited Karyopharm Therapeutics in Q2 2020, selling an estimated $3.44M.
- EAM Investors's ten largest holdings make up 11% of its $452M portfolio in Q2 2020.
- EAM Investors opened 147 new positions and closed 97 in Q2 2020.
- EAM Investors's portfolio value rose 40% quarter-over-quarter to $452M.
Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.